Paper Details

  1. Home
  2. Paper Details

Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.

Author: ElewskiBoni E, GottliebAlice B, KarpovAlexander, KrellJames, LebwohlMark, McLeodLori D, MordinMargaret, NyiradyJudit, PapavassilisCharis, PoppGeorg, SepteMarcis, SigurgeirssonBárður, SinclairRodney, StonkusSigitas, StroberBruce, TranMary H, ZhaoYang

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Secukinumab is a medication for moderate to severe psoriasis that targets a protein involved in inflammation. This study examines how this medication affects itching, pain, and scaling in psoriasis, using a diary to track symptoms.
Paper Details　
Original Abstract of the Article :
Secukinumab is a human interleukin-17A antagonist indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The objective of this analysis was to measure the treatment response on psoriasis-related itching, pain, and scaling...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/ijd.13236

データ提供：米国国立医学図書館（NLM）

Secukinumab: Relief for Psoriasis Symptoms

Psoriasis, a chronic inflammatory skin condition, can significantly impact quality of life, leading to discomfort and social stigma. This study explores the effectiveness of secukinumab, a human interleukin-17A antagonist, in treating moderate to severe plaque psoriasis. The researchers evaluated the impact of secukinumab on psoriasis-related symptoms, such as itching, pain, and scaling, using a patient-reported outcome measure called the Psoriasis Symptom Diary (PSD).

Secukinumab Provides Relief from Psoriasis Symptoms

The study showed that secukinumab significantly improved patient-reported psoriasis symptoms, providing relief from itching, pain, and scaling. The researchers found that secukinumab was effective in reducing these symptoms, leading to a better quality of life for patients with moderate to severe plaque psoriasis.

Hope for Managing Psoriasis Symptoms

This study offers hope for patients struggling with the debilitating symptoms of psoriasis. The findings suggest that secukinumab can be a valuable tool in managing these symptoms and improving quality of life. The research underscores the importance of treating psoriasis not just for its cosmetic impact but also for its significant impact on overall well-being.

Dr.Camel's Conclusion

This study is a refreshing breeze across the hot sands of psoriasis research, offering a glimmer of hope for those suffering from this chronic skin condition. Secukinumab, with its ability to alleviate itching, pain, and scaling, is a beacon of relief in a challenging landscape.

Date :
  1. Date Completed 2017-01-09
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

26866518

DOI: Digital Object Identifier

10.1111/ijd.13236

Related Literature

Article Analysis
・Effective treatment of psoriasis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.